GLS | INSTITUTE

GLS INSIGHTS™

CLINICAL DEVELOPMENT AND GLOBAL HEALTH · BENCHMARK SERIES

The Future of Clinical Trials in Africa

The Future Architecture of Global Clinical Development

How Research Ecosystems Evolve — Outlook 2035

PART III OF III

ANALYTICAL DOMAINS

ARCHITECTURE

CONVERGENCE

EARLY DEVELOPMENT

MATURITY INDEX

SOVEREIGNTY

Guosa Life Sciences

Advancing Life Through Better Medicine

Charles Oviawe · GLS Institute

Published by GLS Institute · Founded by Guosa Life Sciences · 2026

The Series and Its Architecture

This is the final report in a three-part benchmark series. The series has a single argument, examined from three angles. Part I established why representative science and ecosystem development matter. Part II showed how operational excellence turns ecosystems into sustainable research capacity. Part III examines how those ecosystems evolve: how technological, regulatory, and geopolitical change is reshaping the architecture of global clinical development itself.

To keep the three parts intellectually unified rather than topically separate, the series rests on one master framework. Each report examines a different layer of the same architecture rather than introducing a new model.

The GLS Adaptive Clinical Development Ecosystem™

In this architecture, nine capabilities reinforce one another. People build trust; trust enables scientific capacity; capacity and convergence attract investment; digital intelligence multiplies their reach; together they generate representative evidence, healthcare innovation, commercial ecosystems, and ultimately population-health impact.

Figure 1. The GLS Adaptive Clinical Development Ecosystem™, the master architecture of the series. *Source: GLS Institute.*

Part I addressed the foundation of this architecture (people, trust, scientific capacity); Part II addressed its operation (convergence, quality, execution); Part III addresses its evolution: how digital intelligence, representative evidence, and commercial ecosystems are now reshaping the whole. The early-development argument introduced in Part II as the GLS Early Development Thesis™ recurs here as one mechanism of that evolution; the naming is deliberately consistent across the series.

A Note on Method, Evidence, and Foresight

This report distinguishes three kinds of content, and signals which is which. **Evidence** is observable fact: published data, regulatory developments, demographic trends, and market signals, referenced to primary sources current to 22 July 2026. **Interpretation** is what GLS Institute judges that evidence to mean. **Foresight**, concentrated in the scenarios and outlook, is explicitly probabilistic, identifying structural forces and uncertainties rather than predicting events. Where this report introduces an original measure, the GLS Research Ecosystem Maturity Index, it is presented as a transparent, illustrative prototype with its methodology and limitations stated[13], not as a definitive ranking.

Executive Summary

History rarely turns on a single breakthrough. It turns when several structural forces converge and reinforce one another. Clinical development is in such a period. Artificial intelligence is reshaping evidence generation; precision medicine is redefining disease classification; and regulatory systems, demographic shifts, manufacturing strategies, and geopolitics are together changing where innovation occurs and how medicines reach patients.

Africa is increasingly part of this transformation, not as an alternative venue for trials, but as a connected contributor to the global research enterprise. The change is measurable. Eight national regulators meet WHO maturity level 3 as of the most recent WHO benchmarking[4]; the African Medicines Agency has signed cooperation frameworks with both the US FDA and the WHO[2][3]; and a continental push aims to lift local vaccine manufacturing from under 1% today toward 60% by 2040[5]. These are not isolated developments. Together they are redefining the architecture of clinical development.

This report frames that change as five structural transitions: from fragmented regulation to convergence; from emergency response to permanent preparedness; from late-stage participation to contribution across the development lifecycle; from digital tools to intelligent research ecosystems; and from isolated markets to globally connected innovation ecosystems. Parts I and II examined the first three at length; this report concentrates on the two that define the future, intelligent ecosystems and connected innovation, and introduces the tools to measure the transition.

The Central Thesis — and How to Test It

> **GLS CENTRAL THESIS**
> *Global clinical development is shifting from geography-driven networks to ecosystem-driven networks. Africa is one of the clearest examples of this transition, but the underlying framework applies to every region. The future belongs not to isolated sites, but to connected ecosystems.*

This thesis is deliberately testable. Rather than asserting that Africa will simply become more important, it makes a claim that future evidence can confirm or weaken. GLS Institute will track the following indicators across editions:

- Growth in African trial participation and its phase distribution
- Expansion of regional regulatory harmonization and use of reliance pathways
- Growth in laboratory, genomic, and biobanking capacity
- Maturation of data-governance and benefit-sharing frameworks
- Increase in early-development and translational activity
- Growth in regional manufacturing and innovation ecosystems
- Investment in workforce and clinical-research training

WHAT WOULD CHANGE THIS THESIS

Intellectual honesty requires naming what would weaken the argument. The thesis is at risk if AMA implementation stalls, if reliance remains theoretical, if research funding contracts further after the 2025 shock[12], if workforce development fails to scale, if data governance becomes restrictive rather than enabling, or if instability disrupts key ecosystems. Each is tracked as an early-warning signal, not assumed away.

SECTION I

From Geography to Ecosystems: Africa in the Global Architecture

For three decades the question about Africa was “Can more trials be conducted there?” That question framed the continent as a destination for research activity. The more relevant question for the coming decade is different: “How will Africa influence the architecture of global clinical development?” That reframing is the heart of this report. Competitiveness will depend less on geographic expansion and more on ecosystem integration: the degree to which regulatory convergence, scientific capacity, digital intelligence, and trusted partnerships reinforce one another across regions.

Africa does not exist in a vacuum. It is one node in a diversified global development network that includes India, Southeast Asia, Latin America, Eastern Europe, the Middle East, and the established markets of the United States and Europe. The strategic question is not whether Africa replaces these regions, it will not, but where it offers differentiated value within a portfolio.

Table 1. Africa within the global development landscape: where it offers differentiated value.

Region	Established strength	Africa’s differentiated contribution
India & South-East Asia	Scale, cost-efficiency, large trial volumes	Genetic diversity and disease profiles absent elsewhere
Latin America	Mature oncology and cardiometabolic networks	Younger demographics; future demand growth
Eastern Europe	Fast recruitment, established sites	Infectious-disease and vaccine R&D depth
Middle East	Investment capacity; precision-medicine ambition	Regional harmonization momentum (AMA, RECs)
US & Europe	Innovation origin; regulatory reference	Representative evidence and emerging early-development capability

EVIDENCE Eight African regulators meet WHO maturity level 3 as of the most recent WHO benchmarking, and the AMA has signed cooperation frameworks with the US FDA and WHO[4][2][3].

GLS INTERPRETATION These are the institutional preconditions for ecosystem integration. A connected regulatory layer is what allows distributed national capabilities to function as a single network rather than a set of isolated sites.

STRATEGIC IMPLICATION Sponsors should evaluate regional regulatory ecosystems and reliance pathways, not only country-by-country requirements, when designing multi-country programs, and should position Africa for the value it uniquely adds rather than benchmarking it on cost alone.

> **GLS INSTITUTE PERSPECTIVE**
> *The future of clinical development is not a contest between regions. It is the construction of a connected architecture in which each region contributes differentiated value. Africa’s contribution, genetic diversity, representative evidence, and converging regulation, is becoming structural, not marginal.*

SECTION II

Intelligent Research Ecosystems: AI, Data, and Digital Evolution

The fourth structural transition is from digital tools to intelligent research ecosystems. Electronic data capture, decentralized trials, remote monitoring, and analytics are becoming embedded infrastructure; the frontier is now artificial intelligence applied to feasibility, protocol design, patient matching, pharmacovigilance, and evidence generation. For Africa, this transition carries both a singular opportunity and a singular risk.

The opportunity is leapfrogging: ecosystems that build digital infrastructure now can adopt intelligent methods without unwinding legacy systems. Pan-African initiatives are already laying the groundwork,
the Data Science for Health Discovery and Innovation in Africa program, the Africa CDC Pathogen Genomics Initiative, and the H3ABioNet bioinformatics network are building the data and analytic capacity on which intelligent research depends[7].

The risk is representational. Artificial intelligence trained predominantly on non-African data will generalize poorly to African patients, the same representation gap that defines the trial landscape, now encoded in algorithms. With Africa contributing under 2% of global genomic data[1], AI-enabled medicine built without African data risks widening, not closing, the equity gap. Digital transformation must therefore complement, never replace, local expertise, representative data, and community trust.

EVIDENCE Africa supplies under 2% of genomic research data even as decentralized and AI-enabled methods scale globally[1].

GLS INTERPRETATION Intelligent research ecosystems will only serve African populations if they are trained on representative data. The digital transition is inseparable from the representativeness argument that opened the series.

STRATEGIC IMPLICATION Sponsors and developers should treat African data generation and governance as a prerequisite for credible AI-enabled evidence, not an afterthought, and invest in local digital and analytic capacity as core infrastructure.

> **GLS INSTITUTE PERSPECTIVE**
> *Digital intelligence amplifies whatever data it is given. Built on representative African data, it can accelerate equitable medicine; built without it, it will automate the representation gap. The choice is being made now.*

SECTION III

Precision Medicine and Genomic Sovereignty

Precision medicine is redefining disease classification, and it depends on genomic diversity. Here Africa holds a paradox at the center of its strategic position: African populations are the most genetically diverse on Earth, yet contribute under 2% of global genomic research data[1][7]. The science cannot be completed without African genomes; the data to complete it barely exists.



Figure 2. The genomic representation paradox. *Source: H3Africa and genomics-equity literature; GLS Institute.*

This is beginning to change through African-led science. The Human Heredity and Health in Africa consortium has built local genomic capacity and generated hundreds of publications and large biobank datasets, governed by an African data-and-biospecimen access framework[7]; SickleInAfrica and national genome initiatives are extending it. The strategic question is no longer only scientific but one of governance and sovereignty.

Governance, Ethics, and Scientific Sovereignty

Sophisticated readers expect a serious treatment of governance, because precision medicine in Africa raises questions that determine whether collaboration is sustainable: data protection and cross-border transfer, material transfer agreements for biospecimens, genomic-data and intellectual-property governance, benefit-sharing, responsible AI, community consent, and data sovereignty[8]. History makes these questions sharp, extractive research that removed samples and value without reciprocity is precisely what erodes the trust on which the whole architecture depends.

EVIDENCE African populations are the most genetically diverse yet most under-represented in genomic data, and governance frameworks for data, biospecimens, and benefit-sharing are still maturing[7][8].

GLS INTERPRETATION Genomic sovereignty is not an obstacle to precision medicine in Africa; it is its precondition. Trusted, reciprocal governance is what allows diverse data to be generated and shared at all.

STRATEGIC IMPLICATION Sponsors and research partners should build transparent data-governance, benefit-sharing, and trusted-research-environment models from the outset, treating scientific sovereignty as a foundation for collaboration rather than a barrier to it.

GLS INSTITUTE PERSPECTIVE

Scientific collaboration is strongest when governance is transparent, ethical, reciprocal, and trusted. Africa's genetic diversity is a global scientific asset; whether the world can access it depends on whether the terms are sovereign and fair.

SECTION IV

From Aid to Industry: Regional Manufacturing and Health Sovereignty

The fifth transition is from isolated markets to connected innovation ecosystems, and its most concrete expression is manufacturing. The COVID-19 pandemic exposed the cost of dependence: Africa imports roughly 95% of its medicines and 99% of its vaccines, and manufactures under 1% of the vaccines it uses[5]. The 2025 funding shock that closed Part I reinforced the lesson[12]. Sovereignty has become a strategic objective, not a slogan.



Figure 3. Africa's vaccine-manufacturing sovereignty gap. *Source: African Union / Africa CDC; Lancet Global Health, 2025.*

The response is an industrial build-out. The African Union and Africa CDC target 60% local manufacture of vaccines, medicines, and diagnostics by 2040, a goal tied to a continental market valued near USD 50 billion[5]. The institutions are emerging: the WHO mRNA technology-transfer hub at Afrigen in Cape Town; BioNTech's modular mRNA facility in Kigali; the Institut Pasteur de Dakar, long the only African producer of a WHO-prequalified vaccine, expanding through its MADIBA and VaxSen programs; and established players such as Biovac and Aspen in South Africa and Vacsera in Egypt[6]. Regulatory convergence is the enabler: only ecosystems with mature regulators can host production for prequalification, which is why the eight maturity-level-3 regulators and the AMA matter as much to manufacturing as to trials.

This is the link back to clinical development. Manufacturing and research co-locate: a continent that develops, tests, and makes its own medicines closes the loop from discovery to access on its own soil. The transition from aid to industry is also a transition from research destination to innovation partner.

EVIDENCE Africa manufactures under 1% of its vaccines but targets 60% by 2040, backed by a maturing regulatory layer and new facilities from Cape Town to Kigali to Dakar[5][6].

GLS INTERPRETATION Manufacturing sovereignty and research capability are two faces of the same ecosystem. Regulatory maturity, workforce, and trust serve both; investment in one strengthens the other.

STRATEGIC IMPLICATION Sponsors and investors should view regional manufacturing, regulatory maturity, and clinical-development capacity as an integrated opportunity, and recognize that the funding shock makes locally anchored, sovereignty-oriented models more resilient than donor-dependent ones.

> **GLS INSTITUTE PERSPECTIVE**
> *The most consequential shift of the coming decade may be Africa's move from importing finished science to producing it. A continent that makes its own medicines is no longer a venue for development; it is an author of it.*

SECTION V

Measuring the Transition: The GLS Research Ecosystem Maturity Index™

An institute is cited for its measures. To move the series beyond narrative, GLS Institute introduces the first of a planned family of benchmark indices: the GLS Research Ecosystem Maturity Index. It scores ecosystems across the dimensions that determine whether they can support modern clinical development, combining objective indicators with structured judgment. The version below is an illustrative prototype, its purpose is to demonstrate a transparent, repeatable method, not to issue a definitive ranking[13].

Table 2. Index construction: five weighted dimensions.

Dimension	Weight	Illustrative indicators
Regulatory maturity	25%	WHO maturity level (ML3); reliance-MoU participation; RCORE status
Scientific & trial capability	25%	Trial-center depth; first-in-human capability; anchor institutions
Manufacturing & sovereignty	20%	Vaccine/medicine production capability; WHO-prequalification readiness
Genomic & digital capability	15%	Genomic and bioinformatics capacity; data infrastructure
Convergence & sustainability	15%	Regional integration; financing diversification

The eleven ecosystems scored below comprise the eight profiled in Part I plus Egypt, Rwanda, and Senegal, which are central to the regulatory and manufacturing picture developed in Parts II and III. Zimbabwe, the eighth maturity-level-3 authority, is not yet scored because its documented trial-center and manufacturing indicators are too thin for a defensible composite; it is a candidate for the next edition. Coverage is a limitation of the prototype, not a judgment about the ecosystems omitted.



Figure 4. The GLS Research Ecosystem Maturity Index™ (illustrative prototype). *Source: GLS Institute analysis, 2026, drawing on WHO, Africa CDC, IQVIA, and institutional sources.*

The index does analytical work precisely because it is multi-dimensional. South Africa leads on the strength of regulatory maturity, scientific depth, manufacturing, and genomics together. But the rankings also reveal divergences a single measure would hide: Kenya and Uganda score high on scientific capability yet have not reached regulatory maturity level 3, while Rwanda and Senegal rise on regulatory and manufacturing strength despite a narrower trial base. Maturity is not one thing, and ecosystems advance unevenly across its dimensions. Where composite scores tie, ecosystems are listed alphabetically.

Table 3. Index readout: leading strengths and key gaps (illustrative).

Ecosystem	Score	Band	Leading strength	Key gap
South Africa	90	Advanced	Science, manufacturing, genomics	Funding resilience post-2025
Egypt	73	Established	Regulatory; oncology trial base	Genomic & digital depth
Ghana	72	Established	Standard-setting regulator (RCORE)	Manufacturing scale
Rwanda	72	Established	Regulatory; mRNA manufacturing	Scientific trial depth
Senegal	72	Established	Vaccine manufacturing (IPD)	Trial-base breadth
Kenya	71	Established	Scientific capability (KEMRI-Wellcome)	Regulatory maturity (not ML3)
Nigeria	69	Established	Scale; regulatory (NAFDAC)	Capacity concentration

Ecosystem	Score	Band	Leading strength	Key gap
Tanzania	63	Developing	Regulatory (ML3); EAC integration	Manufacturing & genomics
Uganda	63	Developing	HIV/TB science (Makerere)	Regulatory maturity
Mali	52	Developing	Malaria-research specialization	Breadth across dimensions
Ethiopia	49	Emerging	Demographic scale	Most dimensions early-stage

Methodology and Limitations

Scores combine objective indicators (WHO maturity level, documented trial-center counts, manufacturing capability, regulatory-reliance participation) with structured qualitative assessment, weighted as in Table 2 on a 0–100 scale; composites are rounded half-up and ties broken alphabetically. The prototype has real limitations, stated plainly: weights are judgment-based and would benefit from expert calibration; several indicators rest on partial public data; coverage is incomplete; the index measures ecosystem capability, not trial-conduct quality; and a single composite necessarily compresses genuine multi-dimensional difference. The Index should also be read alongside, not in place of, the five-level Maturity Model introduced in Part I: the Model is a descriptive ladder that includes a Strategic Innovation Hub level, while the Index reports four bands and does not yet score for that level, which no ecosystem is judged to have reached. It is offered as a transparent, improvable instrument, to be refined, challenged, and updated annually, not as a final verdict.

SECTION VI

Outlook 2035: Three Scenarios

Foresight is not prediction. A benchmark publication should not present a single inevitable future but a set of plausible ones, each driven by identifiable forces and watched through early-warning indicators. GLS Institute frames the decade to 2035 as three scenarios.

Table 4. Three scenarios for Africa's role in global clinical development to 2035.

Scenario	Key drivers	Principal risks	Early-warning indicators
1. Incremental Progress	Gradual trial growth; partial harmonization	Regulatory fragmentation and infrastructure variability persist	Reliance pathways stay theoretical; ML3 count stalls
2. Accelerated Integration	AMA operationalizes; reliance scales; digital and partnership investment	Funding instability; uneven regional progress	Rising reliance use; ML3 expansion; manufacturing facilities online
3. Innovation Leap	Africa contributes to platform trials, precision medicine, AI-enabled evidence, and regional manufacturing	Sovereignty and governance disputes; talent and capital constraints	First-in-human growth; local genomic data share rising; exports of African-made products

These scenarios are not equally likely, and the difference between them is largely a matter of choice and investment rather than fate. The same drivers, regulatory convergence, digital and genomic capacity, manufacturing, financing, and trust, appear in each; what varies is whether they are resourced and connected. The indicators in the final column are the signals GLS Institute will track to judge which path is unfolding.

> **GLS INSTITUTE PERSPECTIVE**
> *The decade to 2035 will not be decided by technology alone but by whether ecosystems are built to connect. Incremental progress is the default; accelerated integration and an innovation leap are choices, and the early-warning indicators will reveal which choice is being made long before the outcome is settled.*

SECTION VII

Counterarguments

A serious benchmark engages the strongest objections to its own thesis. Three credible counterarguments deserve direct answers.

Counterargument	GLS Institute response
“Africa remains too fragmented for large-scale clinical development.”	Fragmentation is real but no longer the whole story. Regional harmonization, AMA coordination, reliance pathways, and cross-border partnerships are creating more connected ecosystems; eight ML3 regulators and two continental cooperation frameworks signed in 2026 are evidence of convergence, not fragmentation.
“Infrastructure remains too variable.”	Variability matters, but mature development increasingly depends on ecosystem design, site selection, logistics, digital oversight, and quality-by-design rather than uniform physical infrastructure. The maturity index is precisely a tool for matching programs to demonstrated capability.
“Other regions are more competitive.”	India, Southeast Asia, Latin America, and Eastern Europe remain highly relevant. Africa is not a replacement but an increasingly strategic component of a diversified global architecture, differentiated by genetic diversity, young demographics, future demand, and infectious-disease and vaccine expertise.

GLS INSTITUTE PERSPECTIVE

Each objection contains a truth and stops short of the full picture. Fragmentation, variability, and competition are real constraints, and are precisely the conditions that ecosystem integration is designed to address. The thesis survives its strongest critics.

Closing: The Architecture of the Future

This trilogy is not, finally, a report about Africa. It is a report about the future architecture of global clinical development, using Africa as one of the clearest and most strategically important case studies of a transformation underway everywhere.

The future competitiveness of clinical development will increasingly be determined by the ability to build adaptive, trusted, and connected research ecosystems. Africa offers one of the most compelling demonstrations of that shift, a continent moving from research destination toward research author, from importer toward producer, from late-stage participant toward contributor across the development lifecycle. The first-in-human BRILLIANT 011 HIV vaccine trial launched in Cape Town in January 2026[9], and the emergency research response to the 2026 Bundibugyo Ebola outbreak[10], are early markers of that shift. But the underlying principles apply to every region seeking to strengthen scientific innovation, representative evidence, and long-term healthcare impact.

> **THE GLS INSTITUTE POSITION**
> *The next generation of clinical-development leadership will not be defined solely by where organizations conduct trials, but by where they invest in people, trust, regulatory capacity, digital intelligence, representative science, and sustainable healthcare ecosystems. This is the analytical foundation of the GLS Insights™ trilogy.*

Analytical Discipline of This Benchmark

For transparency, the elements below summarize the analytical structure applied across this report and the series.

Element	Purpose
Testable central thesis	Defines an argument future evidence can confirm or weaken
Evidence / interpretation / implication	Separates fact from judgment from recommendation
Master architecture	Gives the trilogy one intellectual backbone
Benchmark index	Makes ecosystem maturity measurable and improvable
Scenario analysis	Handles uncertainty without false prediction
Counterarguments	Engages the strongest objections directly
What would change the thesis	States the conditions that would weaken the argument
Methods & limitations	Supports citation and protects integrity

References

[1] IQVIA (2025) and WHO ICTRP (2026): Africa hosted ~4% of global clinical trials in 2023, supplies <2% of genomic research data, with participation concentrated in Phases III–IV.

[2] African Medicines Agency & US Food and Drug Administration. Statement of Cooperation, June 2026; FDA African Medicines Agency Liaison Office (AMALO), Kigali.

[3] World Health Organization & African Medicines Agency. Framework Agreement for Collaboration, signed at the 79th World Health Assembly (WHA79), May 2026: advancing harmonization, convergence, and reliance.

[4] WHO Global Benchmarking Tool (GBT). As of the most recent benchmarking (January 2025), eight African national regulatory authorities had attained Maturity Level 3: Egypt, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania, and Zimbabwe.

[5] African Union / Africa CDC. Target of 60% local manufacturing of vaccines, medicines, and diagnostics by 2040; Africa currently manufactures <1% of its vaccines and imports ~95% of medicines and ~99% of vaccines; continental market valued near USD 50 billion. (Africa CDC; Lancet Global Health, 2025.)

[6] Lancet Global Health (2025), “A landscape analysis of the vaccine ecosystem in Africa”; and African vaccine-manufacturing landscape: WHO mRNA hub at Afrigen (Cape Town), BioNTech (Kigali), Institut Pasteur de Dakar (MADIBA / VaxSen), Biovac and Aspen (South Africa), Vacsera (Egypt).

[7] H3Africa (Human Heredity and Health in Africa), H3ABioNet, Data Science for Health Discovery and Innovation in Africa (DS-I Africa), and the Africa CDC Pathogen Genomics Initiative; African genetic diversity and genomic underrepresentation (Nature Communications; Oxford Human Molecular Genetics, 2025).

[8] Munung N.S. et al. “Genomics and Health Data Governance in Africa.” Hastings Center Report, 2024, on data sovereignty, benefit-sharing, and ethical governance of African genomic data.

[9] South African Medical Research Council. BRILLIANT 011 first-in-human HIV vaccine trial, Cape Town, January 2026.

[10] World Health Organization. Ebola outbreak, DRC 2026 (Bundibugyo virus); PHEIC declared 17 May 2026; WHO–AMA and partner coordination on trial design during the response. Case and mortality figures as of 22 July 2026; see Part II, Section IV.

[11] Access to Medicine Foundation (2025): Ghana WHO maturity level 3 and Regional Centre of Regulatory Excellence; rise in industry-sponsored and sickle cell trials.

[12] Health Policy Watch and IAVI (2025): withdrawal of major external research funding and its impact on African research capacity (the “2025 funding shock”).

[13] GLS Institute analysis (2026): GLS Research Ecosystem Maturity Index prototype, methodology, weighting, and limitations as described in Section V. Illustrative; for refinement and annual update.

About the Author

Charles Oviawe — *Co-Founder and Managing Partner, Guosa Life Sciences*

Charles Oviawe is a global clinical research executive and quality systems professional with more than two decades of experience supporting pharmaceutical, biotechnology, government, and global health organizations across the clinical development lifecycle.

His expertise spans Phase I through Phase IV clinical development, quality management systems, regulatory affairs, pharmacovigilance, laboratory quality, Good Clinical Practice, Good Laboratory Practice, Good Pharmacovigilance Practice, current Good Manufacturing Practice, and Computer System Validation.

Before founding Guosa Life Sciences, he held senior quality assurance and research and development leadership positions with Pfizer, Acadia, Shionogi Inc., BeyondSpring, and Forest Laboratories, supporting global clinical development programs across multiple therapeutic areas and contributing to inspection readiness, quality systems implementation, and global regulatory compliance.

Through Guosa Life Sciences he has advised pharmaceutical sponsors, biotechnology companies, contract research organizations, academic institutions, and public health organizations on clinical operations, quality systems, regulatory strategy, pharmacovigilance, and global research capacity development.

He is the architect of the GLS Clinical Development Network and the African Early Phase Clinical Research Network, initiatives designed to strengthen evidence-based institutional qualification, foster scientific collaboration, and expand sustainable Phase I clinical research capacity across Africa and other emerging markets.

About GLS Institute

GLS Institute is the clinical development and global health research division of Guosa Life Sciences. Its benchmark publications examine the forces reshaping where and how medicines are developed, with the aim of advancing better life through better medicine.

The Institute publishes independently of the commercial engagements of Guosa Life Sciences. Its benchmark studies are self-funded, and are not commissioned, sponsored, or subject to client review. Where the analysis touches on services the firm provides, that interest is disclosed rather than omitted. https://guosalifesciences.com/institute/index.html

About Guosa Life Sciences

Advancing Global Clinical Development Through Local Expertise

Guosa Life Sciences is a global contract research organization and strategic consulting firm supporting pharmaceutical, biotechnology, medical device, diagnostic, and global health organizations throughout the clinical development lifecycle.

GLS delivers integrated services spanning Phase I through Phase IV clinical research, regulatory affairs, quality assurance, pharmacovigilance, laboratory oversight, biometrics, medical writing, project management, logistics, and strategic advisory services.

With headquarters in the United States and an operational footprint across Sub-Saharan Africa and Asia, together with strategic partnerships in Europe, the Middle East, and other emerging markets, GLS combines global quality standards with in-country operational expertise.

Core service areas

- Clinical operations
- Quality assurance and compliance
- Regulatory affairs
- Pharmacovigilance
- Medical and scientific affairs
- Data management and biostatistics
- Laboratory services
- Supply chain and logistics
- Project management
- Global health research
- Strategic consulting

Strategic initiatives

GLS Clinical Development Network (GLS-CDN). A collaborative operational network connecting qualified research institutions, investigators, laboratories, and operational specialists to support evidence-based institutional qualification and multi-country clinical development.

African Early Phase Clinical Research Network (AE-PCRN). A scientific collaboration focused on strengthening Phase I clinical research readiness, institutional capacity, and sustainable early clinical development across Africa through collaboration, training, and evidence-based institutional qualification.

Guosa Life Sciences
Advancing Life Through Better Medicine